Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature

Abstract

Isolated extramedullary relapse of acute lymphoblastic leukemia (ALL) occurs in soft tissues and various organs outside the testis and central nervous system. Treatments such as hematopoietic stem cell transplantation and more novel modalities such as immunotherapy have eradicated ALL at extramedullary sites. In some instances, survival times for relapsed ALL at these sites are longer than those for relapsed disease involving only the bone marrow. Isolated relapse of ALL in the myocardium is rare, especially in children, making diagnosis and treatment of it difficult. More recent treatment options such as chimeric antigen receptor T-cell therapy carry a high risk of cytokine release syndrome and associated risk of worsening cardiac function. Herein we present the case of an 11-year-old boy who presented with relapsed symptomatic B-cell ALL in the myocardium following allogeneic hematopoietic stem cell transplantation. This is an unusual presentation of relapsed ALL and this case demonstrates the associated challenges in its diagnosis and treatment. The case report is followed by a literature review of the advances in treatment of pediatric leukemia and their application to extramedullary relapse of this disease in particular.

A Multicenter Cohort Study on Children Suffering from Acute Lymphoblastic Leukemia: Effects of Obesity on Mortality

“…So far, there is no evidence that the most suitable patients to adjust for medication and stress require chemotherapy for weight and obesity. This may cause the patient to receive oxygen pills, which increases the risk of toxins or reemergence [ 21 ].…”

Radiotherapy in Philadelphia chromosome‑positive acute lymphoblastic leukemia with pericardial invasion after transplantation: A case report

“…Among these cases, six individuals with leukemia and lymphoma received radiotherapy at doses of 15-20 Gy over 1.5-2 weeks, resulting in continuous CR lasting for 2-4 months, with a clinical improvement rate of 60% (6). However, in a further study, 2 cases of leukemia with cardiac infiltration experienced recurrent and uncontrollable heart failure within 6 months, leading to death (10,11).…”

N-Ethyl-N-Nitrosourea Induced Leukaemia in a Mouse Model: Protective Effect of Icaritin via Inhibition of IL-6/JAK2/STAT3 Pathway Causes Apoptosis

“… 14 Leukemia treatments encompass various approaches, such as radiation, bone marrow transplants, and surgery. 15 However, while rapid restorative therapies, such as targeted molecular therapies or immune-based treatments, can lead to near-complete remission, they may also result in disease recurrence, resistance, progression, and ultimately death. Radiation and chemotherapy, commonly employed in leukemia treatment, carry risks, including potential side effects such as bone marrow suppression, increased susceptibility to infections, hair loss, fatigue, and gastrointestinal disturbances.…”